Literature DB >> 26104644

Oxygenation of the placenta and its role in pre-eclampsia.

Berthold Huppertz1.   

Abstract

Proper oxygenation of the placenta and hence the embryo/fetus is essential for a successful pregnancy. During the first trimester of pregnancy the partial pressure of oxygen in the placenta and the embryo is very low and does not exceed 20mmHg. At the end of the first trimester maternal blood flow towards the placenta is established leading to a sudden increase in placental oxygenation to about 50-60mmHg. This level of oxygenation is keptuntil delivery. One of the numerous hypotheses to describe the etiology of preeclampsia, which is still the most cited hypothesis today, is based on a failure of extravillous trophoblast to invade the uterine spiral arteries in the placental bed. This in turn is believed to result in placental hypoxia and subsequently to damage of the villous trophoblast. Following this hypothesis, there is a series of events following these hypoxic conditions of the placenta. There is a large number of articles published that have investigated the effect of different oxygen concentrations on the phenotype of trophoblasts in vitro and have used this data to corroborate the hypothesis above. Unfortunately, one important aspect has not been addressed until recently: What is the placental oxygen concentration in placental pathologies such as preeclampsia in vivo? All studies that have tried to elucidate the placental oxygen concentration have done this indirectly, since direct measurements of placental oxygen in the third trimester of pregnancy have been defined as unethical. Not a single of such studies has revealed that oxygenation of the placenta in pregnancy pathologies is decreased. At the same time a number of studies have shown that in intra-uterine growth restriction (IUGR) placental oxygenation is increased rather than decreased. This has been shown to be true in the presence and absence of preeclampsia. This data clearly disprove the above hypothesis and should open our minds to decipherthe realcauses of preeclampsia.
Copyright © 2014.

Entities:  

Year:  2014        PMID: 26104644     DOI: 10.1016/j.preghy.2014.04.016

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  6 in total

Review 1.  The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.

Authors:  Frederick Schatz; Ozlem Guzeloglu-Kayisli; Sefa Arlier; Umit A Kayisli; Charles J Lockwood
Journal:  Hum Reprod Update       Date:  2016-02-23       Impact factor: 15.610

2.  Hypoxia-Induced Activation of JAK/STAT3 Signaling Pathway Promotes Trophoblast Cell Viability and Angiogenesis in Preeclampsia.

Authors:  Chengfang Xu; Xuejiao Li; Peiling Guo; Jia Wang
Journal:  Med Sci Monit       Date:  2017-10-14

3.  Placental Hypoxia During Early Pregnancy Causes Maternal Hypertension and Placental Insufficiency in the Hypoxic Guinea Pig Model.

Authors:  Loren P Thompson; Laramie Pence; Gerald Pinkas; Hong Song; Bhanu P Telugu
Journal:  Biol Reprod       Date:  2016-11-02       Impact factor: 4.285

Review 4.  Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.

Authors:  Hamutal Meiri; George Osol; Irene Cetin; Sveinbjörn Gizurarson; Berthold Huppertz
Journal:  Comput Struct Biotechnol J       Date:  2017-09-22       Impact factor: 7.271

5.  First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Katarina Ivankova; Ladislav Krofta
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

6.  Evaluation of the human placenta optical scattering properties using continuous wave and frequency-domain diffuse reflectance spectroscopy.

Authors:  Siddharth M Khare; Thien Nguyen; Afrouz A Anderson; Brian Hill; Roberto Romero; Amir H Gandjbakhche
Journal:  J Biomed Opt       Date:  2020-11       Impact factor: 3.170

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.